人民财讯8月13日电，智翔金泰(688443)8月13日晚间公告，近日公司就"一项评价GR1802注射液联合背 景治疗在季节性过敏性鼻炎患者中的有效性和安全性的随机、双盲、安慰剂对照、多中心III期临床试 验"的开展，完成与国家药监局药品审评中心EOP2(II期临床试验结束/III期临床试验启动前)的会议沟 通，公司将正式启动该III期临床试验。 ...

Group 1 - Huadong Medicine's subsidiary has obtained exclusive commercialization rights for the oral JAK1 inhibitor VC005 from Jiangsu Weikail. The company will pay an upfront fee of 50 million RMB and up to 180 million RMB in milestone payments [1] - VC005 is a novel, potent, and highly selective second-generation oral JAK1 inhibitor currently in clinical development for treating inflammatory and autoimmune diseases, with its fastest clinical progress in Phase III for moderate to severe atopic dermatitis [1] Group 2 - Jidan Bio, as the controlling shareholder of Jingchuan Diagnostics, has faced difficulties in understanding the operational status of Jingchuan due to communication issues, leading to a lawsuit for access to financial data [2] - The final ruling requires Jingchuan Diagnostics to provide company documents and financial reports for review by Jidan Bio and its authorized representatives, highlighting management challenges faced by listed companies over their subsidiaries [2] Group 3 - Zhixiang Jintai announced the resignation of two core technical personnel, with one leaving for personal development and the other due to work adjustments, while a new core technical member has been appointed [3] - The biotech industry relies heavily on core technical teams, and while personnel changes are common, the focus should be on the new members' professional backgrounds and alignment with the company's strategy [3] Group 4 - Haisike's innovative drug HSK47977 has received approval for clinical trials, targeting BCL6 protein to inhibit tumor cell development, specifically for non-Hodgkin lymphoma treatment [4] - HSK47977 is a potential first-in-class product with strong anti-tumor activity and selectivity, showing promising results in preclinical studies [4] Group 5 - Zhengda Tianqing has had two class 1 new cancer drugs accepted for clinical trials in China, marking a significant expansion in its oncology pipeline [5][6] - The drugs include a Bcl-xL protein degradation-targeting chimeric compound and a highly selective PARP1 inhibitor, both aimed at treating malignant tumors [5]

Core Viewpoint - The company has announced adjustments in its core technical personnel, including the resignation of two key individuals and the addition of a new core technical member, which is not expected to adversely affect its operations or core competencies [2][3][9]. Group 1: Management Changes - Mr. Chang Zhiyuan, the former Deputy General Manager and core technical personnel, has resigned due to personal development and will no longer hold any position within the company [2][3]. - Mr. Shan Jikuan has also been removed from the list of core technical personnel due to work adjustments [2][3]. - The company expresses gratitude for Mr. Chang's contributions during his tenure [3]. Group 2: New Core Technical Personnel - Ms. Zhou Xiaowei has been newly recognized as a core technical personnel member, with a background in genetics and experience in military medical research [8]. - The company emphasizes that the adjustment of core technical personnel will not impact its intellectual property rights or operational capabilities [2][6]. Group 3: Impact of Changes - The company maintains a diverse research and development team with expertise in various fields, ensuring that ongoing projects are not disrupted by the personnel changes [9][10]. - The company has confirmed that all research and development activities are proceeding normally and that the adjustments will not affect its core competitiveness or operational sustainability [9][11]. Group 4: Future Measures - The company plans to continue investing in research and development, enhancing its team structure, and increasing the recruitment and training of personnel to boost innovation capabilities [10].

证券代码：688443 证券简称：智翔金泰 公告编号：2025-031 重庆智翔金泰生物制药股份有限公司 关于公司高级管理人员辞职及核心技术人员调 整的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、高级管理人员离任情况 (一) 提前离任的基本情况 公司副总经理、核心技术人员常志远先生因个人发展，已向董事会申请辞去 副总经理职务。常志远先生辞任后，将不再担任公司任何职务。 是否继续在 | | | | 是否存在未 上市公司及 | | | | --- | --- | --- | --- | --- | --- | | | | 原定任期到 | | | | | 姓名 | 离任职务 | 离任时间 | 离任原因 | | 履行完毕的 | | | | 期日 | 其控股子公 | | | | | | | 公开承诺 | | | | | | | 司任职 | | | | 常志远 | 副总经理 | | 个人发展 | 否 | 是 | (二) 离任对公司的影响 常志远先生辞去公司副总经理职务不会对公司日常经营产生不利影响，常志 远先 ...

证券日报网讯 8月12日晚间，智翔金泰发布公告称，公司副总经理、核心技术人员常志远先生因个人发 展，已向董事会申请辞去副总经理职务。常志远先生辞任后，将不再担任公司任何职务。 （文章来源：证券日报） ...

（文章来源：每日经济新闻） 2024年1至12月份，智翔金泰的营业收入构成为：医药制造业占比99.92%，其他业务占比0.08%。 智翔金泰（SH 688443，收盘价：32.86元）8月12日晚间发布公告称，公司经审慎研究，对现有核心技 术人员进行调整：原核心技术人员常志远先生因个人发展申请离职，不再认定为核心技术人员，并将不 再担任公司任何职务；原核心技术人员单继宽先生因工作调整，不再认定为核心技术人员；新增认定周 晓巍女士为公司核心技术人员，其他核心技术人员未发生变化。公司副总经理、核心技术人员常志远先 生因个人发展，已向董事会申请辞去副总经理职务。常志远先生辞任后，将不再担任公司任何职务。 ...

常志远：男，1980 年 1 月出生，中国国籍，无境外居留权，硕士。曾任上 海华新生物高技术有限公司研发部主管、部门经理、总经理助理，上海泽润生物 科技有限公司部门主管、经理、总监，智翔(上海)医药科技有限公司副总经理、 国泰海通证券股份有限公司 关于重庆智翔金泰生物制药股份有限公司 核心技术人员调整的核查意见 根据《证券发行上市保荐业务管理办法》《上海证券交易所科创板股票上 市规则》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》 等有关法律、法规的规定，国泰海通证券股份有限公司（以下简称"国泰海通"、 "保荐机构"）作为重庆智翔金泰生物制药股份有限公司（以下简称"智翔金泰" 或"公司"）首次公开发行股票并在科创板上市持续督导的保荐机构，对智翔金 泰核心技术人员调整事项进行了核查，具体情况如下： 一、核心技术人员调整的具体情况 公司副总经理、核心技术人员常志远先生因个人发展，已向董事会申请辞去 副总经理职务。常志远先生辞任后，将不再担任公司任何职务。截至本核查意见 出具日，常志远先生持有公司股份 2,500,000 股。常志远先生承诺将继续遵守《上 市公司股东减持股份管理暂行办法》《上海证 ...

重庆智翔金泰生物制药股份有限公司 关于公司高级管理人员辞职及核心技术人员调 整的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、高级管理人员离任情况 (一) 提前离任的基本情况 证券代码：688443 证券简称：智翔金泰 公告编号：2025-031 公司副总经理、核心技术人员常志远先生因个人发展，已向董事会申请辞去 副总经理职务。常志远先生辞任后，将不再担任公司任何职务。 | | | | | | | | 是否继续在 | 是否存在未 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 姓名 | 离任职务 | 离任时间 | | 原定任期到 期日 | | 离任原因 | 上市公司及 其控股子公 | 履行完毕的 | | | | | | | | | 司任职 | 公开承诺 | | 常志远 | 副总经理 | 2025 年 8 | 月 | 2027 12 | 年 | 个人发展 | 否 | 是 | | | | 日 11 | | 月 23 | 日 | | ...

Market Overview - The Shanghai Composite Index closed at 3653.50 points, with a change of +0.51% [1] - The total trading volume of A-shares reached 1,149.623 billion yuan [1] Technical Analysis - A total of 17 A-shares experienced a "death cross" where the 5-day moving average fell below the 10-day moving average [1] - Notable stocks with significant distance between their 5-day and 10-day moving averages include: - Angli (002940) with a distance of -1.91% - Chengdu Xian Dao (688222) with a distance of -1.51% - Saiseng Pharmaceutical (300485) with a distance of -1.38% [1] Individual Stock Performance - Angli (002940) saw a daily increase of 2.02% with a turnover rate of 4.48% [1] - Chengdu Xian Dao (688222) increased by 1.47% with a turnover rate of 2.10% [1] - Saiseng Pharmaceutical (300485) experienced a slight decrease of -0.14% with a turnover rate of 3.10% [1] - Other stocks with notable performance include: - Jintai (688443) up by 1.78% - Changshan Pharmaceutical (300255) up by 2.29% - Zhizheng (603991) down by -1.69% [1]

Market Overview - The Shanghai Composite Index is at 3639.18 points with a change of 0.11% [1] - The total trading volume of A-shares is 832.786 billion yuan [1] Stocks with Death Cross - 20 A-shares have seen their 5-day moving average cross below the 10-day moving average [1] - Notable stocks include: - Angli (002940) with a 5-day moving average of 56.59 yuan, down 1.78% from the 10-day moving average [1] - Chengdu Xian Dao (688222) with a 5-day moving average of 23.11 yuan, down 1.64% [1] - Sai Sheng Pharmaceutical (300485) with a 5-day moving average of 14.83 yuan, down 1.40% [1] Additional Stock Data - Other stocks with significant moving average changes include: - Zhi Xiang (688443) with a 5-day moving average of 33.34 yuan, down 0.85% [1] - Changshan Pharmaceutical (300255) with a 5-day moving average of 41.59 yuan, down 0.68% [1] - Zhi Zheng (603991) with a 5-day moving average of 72.69 yuan, down 0.40% [1] Performance Summary - The performance of various stocks shows a mix of slight gains and losses, with some stocks like Angli and Chengdu Xian Dao experiencing notable declines in their moving averages [1][2] - The overall market sentiment appears cautious, reflected in the trading volumes and the number of stocks showing bearish signals [1]